The U.S. Food and Drug Administration today approved Rybelsus
(semaglutide) oral tablets to improve control of blood sugar in adult
patients with type 2 diabetes, along with diet and exercise.
Rybelsus
Glucagon-like peptide (GLP-1)
GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.
No comments:
Post a Comment